3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Leukemia, Myeloid, Acute
18
Myeloproliferative Disorders
4
Glioma
4
Myelodysplastic Syndromes
3
Cholangiocarcinoma
3
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Chondrosarcoma
2
Biliary Tract Neoplasms
2
Xanthogranuloma, Juvenile
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasms, Unknown Primary
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Lymphoma, Follicular
1
IDH1-Mutated Malignancies
1
IDH1 Mutation Myeloid Neoplasms
1
Histiocytic Sarcoma
1
Interventions
pembrolizumab
2
atezolizumab
2
Paclitaxel
2
Carboplatin
2
veliparib
1
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
entrectinib
1
cobimetinib
1
alectinib
1
Whole Genome Sequencing
1
Vemurafenib
1
Transurethral Resection of Prostate
1
Taxes
1
Surveys and Questionnaires
1
Specimen Handling
1
Sequence Analysis, RNA
1
Radiosurgery
1
Magnetic Resonance Spectroscopy
1
HhAntag691
1
Genetic Testing
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Erlotinib Hydrochloride
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Unknown Primary
×
ivosidenib
×
1 year
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts